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Summary 
 
Count n=416 
 
In this issue of Cancer Discovery, Hagel and colleagues report the design and the in 
vitro and in vivo activity of a novel, irreversible, paralog-specific kinase inhibitor of 
FGFR4, BLU9931. This compound binds covalently to a cysteine residue in the hinge 
region of FGFR4 but not in FGFR1-3. BLU9931 induces tumor shrinkage in 
hepatocellular carcinoma models that express a functioning ligand/receptor complex 
consisting of FGF19/FGFR4/KLB and adds to a growing list of anti-FGFR4 agents.  
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Alongside the identification of cancers driven by FGFR activation, the past few years 
have delivered multiple second and third generation anti-FGFR agents. These 
include inhibitors with greater selectivity (e.g. AZD4547 and BGJ398), irreversible 
FGFR kinase inhibitors (FIIN-1, FIIN-2), monoclonal antibodies specific to each 
family member (FGFR1-4), as well as allosteric inhibitors targeting the extracellular 
domain that inhibit receptor internalization (SSR128129E). With respect to the 
competitive kinase inhibitors, the search for greater FGFR selectivity was driven, to 
some extent, by the desire to reduce toxicity associated with VEGFR2 inhibition. 
However, the selection against VEGFR2 was accompanied by a loss of selectivity 
against FGFR4. As a result, almost all the competitive FGFR kinase inhibitors 
currently in Phase I/II trials (AZD4547, BGJ398, JNJ42756493, Bayer1163877, 
Debio1347, LY2874455) show at least a four-fold greater selectivity towards FGFR1-
3 over FGFR4 (1).  
 
Hagel and colleagues (2) report the design and the activity of a FGFR4 specific 
inhibitor, BLU9931, in several models of hepatocellular carcinoma (HCC). This group 
utilized structure-based drug design to create a compound that binds covalently to 
Cys552 in the hinge region of FGFR4. This cysteine is unique to FGFR4, as FGFR1-
3 possess a bulky tyrosine residue, which clashes with BLU9931. As a result of 
modifying Cys552, BLU9931 is a potent and selective FGFR4 inhibitor (IC50 = 3 nM) 
with only weak activity against FGFR1-3 (IC50s range from ~150-600 nM). 
Furthermore, BLU9931 was unable to inhibit the six other kinases that also have a 
cysteine at the corresponding position within the hinge region.  
 
The group at Blueprint Medicines show that BLU9931 inhibits FGFR4 and blocks 
phosphorylation of its substrates FRS2a, MAPK and AKT at 10-30nM in the MDA-
MB-453 breast cancer cell line, carrying an activating Y367C mutation in FGFR4, but 
not in DMS-11 lung cancer cells carrying an amplification of FGFR1. With regards to 
HCC, they confirmed previous reports with pan-FGFR inhibitors showing only cells 
expressing a fully functional receptor complex comprised of FGFR4, its co-receptor 
Klotho-β (KLB) and FGF19 respond to BLU9931 (3). Of the 11 HCC cell lines they 
tested, 4 cell lines expressed all three components and 3 of these, all with FGF19 
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amplification, were sensitive to BLU9931. The authors report that twice-daily 
30mg/kg doses led to tumor shrinkage in the Hep3B xenograft model, however twice 
daily doses of 300mg/kg were required to induce tumor shrinkage in an FGF19 
overexpressing HCC PDX model. Which of these models represents the more 
common effective dose in humans is currently unknown. 
 
Toxicity issues arising from Phase I clinical trials of the FGFR1-3 inhibitors AZD4547, 
BGJ398 and JNJ42756493 indicate that hyperphosphatemia and tissue 
mineralization represent on-target class effects, which can be clinically managed by 
diet modification and drugs. A specific FGFR4 kinase inhibitor is not expected to 
share this toxicity profile. However, one caveat to an improved toxicology profile with 
specific FGFR4 inhibition comes from preclinical toxicology studies with an anti-
FGF19 monoclonal antibody in cynomolgus monkeys (4). Although monoclonal 
antibodies targeting FGF19 and FGFR4 have shown tumor regression in murine 
xenograft models, additional toxicology studies were performed in monkeys given 
they share similar mechanisms of cholesterol turnover and bile acid synthesis with 
humans. Pai and colleagues reported that animals in the 10, 30 and 100mg/kg 
cohorts but not the 2mg/kg cohort had to be euthanized in the subsequent weeks 
after their first dose due to severe diarrhea, low food consumption and decreased 
body weight (4).  Subsequent mechanistic studies revealed increases in multiple liver 
enzymes suggestive of liver toxicity, as well as increased synthesis of multiple bile 
acids and ileal malabsorption of bile acids. Although a similar toxicology profile could 
be expected in monkeys due to specific FGFR4 inhibition with BLU9931, the authors 
propose that the combination of irreversible binding and the shorter half-life of this 
compound (2.3 hours) compared to the anti-FGF19 monoclonal antibody 
(days/weeks) may allow for fine tuning of the dosing schedule to avoid similar 
gastrointestinal toxicity issues. It should be noted that this remains a crucial step in 
the preclinical development of BLU9931.  
 
The design of a specific FGFR4 irreversible inhibitor raises the vexing issue of 
whether better clinical response will be seen with a paralog-specific versus a pan-
FGFR inhibitor, or indeed, a multi-kinase inhibitor. The advantages that come with 
specific FGFR4 inhibition include less toxicity associated with hyperphosphatemia 
and presumably less impairment of wound repair, given the important role that 
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FGFR1-2 plays in epithelial wound repair (1). On the other hand, although FGFR4 is 
the only family member expressed in mature hepatocytes, several studies have 
reported upregulation of FGFR1-3 in HCC (5). This raises the possibility that FGFR4 
inhibition alone may not be sufficient in HCC, or if it is, whether it will result in the 
more rapid emergence of resistance due to kinase switching to other FGFR family 
members. It is interesting to note, that although BLU9931 had much better activity 
than BGJ398 in the breast cancer cell line dependent on Y367C FGFR4 (Figure 2, 
ref 2), similar IC50s were seen with both BLU9931 and BGJ398 in the three sensitive 
HCC cell lines (Table 1, ref 2). The latter data is consistent with these HCC cell lines 
expressing other FGFR family members that are contributing to their BGJ398 
sensitivity. Lastly, another potentially significant disadvantage to paralog-specific 
FGFR4 inhibition would be a reduction in the anti-angiogenic effects associated with 
pan-FGFR inhibition or dual VEGFR/ FGFR inhibition. 
 
The search to identify the “best in class” FGFR inhibitor, in addition to finding the 
right balance between clinical effectiveness and patient toxicity, will involve the ability 
of the new agent to induce lasting tumor regressions and improve overall survival in 
patients. Our understanding of intrinsic and acquired mechanisms of resistance to 
FGFR inhibition is beginning to emerge and, although mechanisms of downstream 
and parallel kinase switching are likely to vary with tissue context (unpublished 
observations), preclinical studies have already confirmed the importance of the 
gatekeeper residue in the FGFRs. The physical proximity between Cys552 and the 
V550 gatekeeper residue suggests that FGFR4 gatekeeper mutations may block 
BLU9931 binding. In addition, irreversible inhibitors that form a covalent bond with a 
cysteine residue are uniquely susceptible to mutations affecting the cysteine residue 
itself. Although not paralog-specific, the second generation of irreversible pan-FGFR 
inhibitors targeting the other conserved cysteine in the hinge region has shown 
activity against multiple gatekeeper mutations in FGFR2-4 (6) and may offer an 
approach to prevent or overcome both FGFR kinase switching and the acquisition of 
gatekeeper mutations. Results from preclinical toxicology studies and/or comparative 
effectiveness studies with these two inhibitors are eagerly anticipated. 
 
As with many kinase inhibitors, the results from early clinical trials suggest that pan-
FGFR inhibition may not be as effective as first hoped. As such, combination 
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approaches with chemotherapy, radiotherapy or other molecularly targeted agents 
are likely to be required. Strategies being investigated in several FGFR-dependent 
malignancies include co-targeting the EGFR or PI3K/mTOR pathways. Within HCC, 
emerging data also implicates the potential importance of co-targeting the STAT3 
pathway.  A variant of FGF19, which carries several missense mutations and a 5 
codon deletion (M70) was shown to retain the ability to metabolically regulate bile 
acid synthesis while having no tumorigenic effect (7). M70 acted as a “biased ligand” 
whereby it shared similar downstream MAPK and PI3K signaling to wildtype FGF19 
but did not activate pro-tumorigenic STAT3 signaling. The M70 molecule therefore 
offers a therapeutic strategy for treating both bile acid metabolism disorders as well 
as HCCs dependent on FGF19/FGFR4/KLB signaling. Insights provided by M70 also 
suggest that should a dosing schedule that avoids gastrointestinal toxicity be 
identified for BLU9931, combination therapy with downstream STAT3 inhibition might 
provide more durable responses.  
 
The development of a specific FGFR4 inhibitor, notwithstanding the potential toxicity 
caveats mentioned above, might also show efficacy in a range of other cancers 
where preclinical data suggests FGFR4 dependency. A subset of 
rhabdomyosarcomas have been shown to carry activating mutations in FGFR4 and 
rare cases of glioblastomas, lung and breast cancers have also carried activating 
FGFR4 mutations. In addition a subset of cancers arising from the lung, ovary, 
prostate thyroid and colon show FGFR4 amplification or high expression, which in 
many cases correlates with aggressiveness and/or poor prognosis (reviewed in 1, 8). 
Interest in targeting FGFR4 has increased, evidenced by the increase in reported 
agents with anti-FGFR4 activity reported in publications, patents (9), recent 
conference abstracts or being trialed in patients (Table 1). Similar to other FGFRs, 
there are also some reports of FGFR4 acting as a tumor suppressor gene in some 
tissue types, suggesting that even with paralog-specific inhibition, some caution 
should be applied in the systemic application of FGFR4 inhibition (reviewed in (8)). 
 
Previous studies suggest that amplification of 11q13.3 could be an effective 
biomarker for HCC patients likely to respond to anti-FGFR4 therapy (10) or 
alternatively, that all molecules in the FGF19/FGFR4/KLB axis need to be expressed 
to predict susceptibility to FGFR4 inhibition (3). The latter scenario was confirmed by 
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Hagel and colleagues. The authors also propose that BLU9931 may also be effective 
in those HCC patients with high FGF19 mRNA expression in the absence of genomic 
amplification. If true, this assertion would result in twice the number of patients 
eligible for anti-FGFR4 inhibition. However no models of HCC tested in this 
manuscript represent this cohort of patients, and further preclinical evidence is 
required. In addition, future trials enrolling only biomarker positive patients may allow 
further refinement of these biomarkers, e.g. are higher expression levels of KLB and 
FGFR4 required to predict response in patients with increased FGF19 expression 
versus those with FGF19 amplification. Moreover, due to the complexity of 
FGF/FGFR biology in different tissues, biomarkers are likely to be different in other 
tumor tissue types e.g. expression of KLB is likely not required in tissues where 
FGFR4 is activated by mutations, amplification and/or the expression of non-
hormonal FGF ligands.  
 
In summary, if BLU9931 can overcome the toxicity issues seen with other anti-
FGF19/FGFR4 therapies, perhaps by optimization of its dosing schedule, it looks to 
be an effective treatment option for a subset of FGFR4-driven cancer types such as 
HCC. The field looks forward with anticipation to additional preclinical and clinical 
data being presented for the various different agents with anti-FGFR4 activity 
presented in Table 1 in the hopes that cancer patients can experience durable 
responses to inhibiting this pathway either alone, or in combination with other anti-
cancer therapies.  
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Table 1. Summary of anti-FGFR4 agents in preclinical  
and clinical development. 
 
Agents Targeting 
FGF19/FGFR4 axis 
Type of Inhibitor 
  
JNJ-42756493a FGFR1-4 kinase, not published 
FGF401 a FGFR1-4 kinase, not published 
LY2874455 a FGFR1-4, kinase, ATP competitive  
SSR128129 FGFR1-4, extracellular domain, allosteric   
BLU9931  FGFR4 kinase, selective irreversible  
AZ709 FGFR4 kinase, not published 
FIIN-1; FIIN-2 FGFR1-4 kinase, irreversible  
1A6  mAb to FGF19  
M70 a FGF19 non-tumorigenic biased ligand  
LD1 mAb to FGFR4  
40-12 mAb to FGFR4  
  
a Currently being tested in clinical trials   
Page	  1	  
REFERENCES 
 
 
 
 1.	   Ho	   HK,	   Yeo	   AH,	   Kang	   TS,	   Chua	   BT.	   Current	   strategies	   for	   inhibiting	   FGFR	  activities	   in	   clinical	   applications:	   opportunities,	   challenges	   and	   toxicological	  considerations.	  Drug	  Discov	  Today.	  2014;19:51-­‐62.	  2.	   Hagel	  M,	  Miduturu	  C,	  Sheets	  M,	  Rubin	  N,	  Weng	  W,	  Stransky	  N,	  et	  al.	  First	  selective	  small	  molecule	  inhibitor	  of	  FGFR4	  for	  the	  treatment	  of	  hepatocellular	  carcinomas	  with	  an	  activated	  FGFR4	  signaling	  pathway.	  Cancer	  Discovery.	  2015.	  3.	   Guagnano	  V,	  Kauffmann	  A,	  Wohrle	  S,	  Stamm	  C,	  Ito	  M,	  Barys	  L,	  et	  al.	  FGFR	  genetic	  alterations	  predict	  for	  sensitivity	  to	  NVP-­‐BGJ398,	  a	  selective	  pan-­‐FGFR	  inhibitor.	  Cancer	  Discov.	  2012;2:1118-­‐33.	  4.	   Pai	   R,	   French	   D,	   Ma	   N,	   Hotzel	   K,	   Plise	   E,	   Salphati	   L,	   et	   al.	   Antibody-­‐mediated	  inhibition	   of	   fibroblast	   growth	   factor	   19	   results	   in	   increased	   bile	   acids	   synthesis	   and	  ileal	   malabsorption	   of	   bile	   acids	   in	   cynomolgus	   monkeys.	   Toxicological	   sciences	   :	   an	  official	  journal	  of	  the	  Society	  of	  Toxicology.	  2012;126:446-­‐56.	  5.	   Sandhu	   DS,	   Baichoo	   E,	   Roberts	   LR.	   Fibroblast	   growth	   factor	   signaling	   in	   liver	  carcinogenesis.	  Hepatology.	  2014;59:1166-­‐73.	  6.	   Tan	   L,	   Wang	   J,	   Tanizaki	   J,	   Huang	   Z,	   Aref	   AR,	   Rusan	   M,	   et	   al.	   Development	   of	  covalent	   inhibitors	   that	   can	   overcome	   resistance	   to	   first-­‐generation	   FGFR	   kinase	  inhibitors.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A.	  2014;111:E4869-­‐77.	  7.	   Zhou	   M,	   Wang	   X,	   Phung	   V,	   Lindhout	   DA,	   Mondal	   K,	   Hsu	   JY,	   et	   al.	   Separating	  Tumorigenicity	   from	   Bile	   Acid	   Regulatory	   Activity	   for	   Endocrine	   Hormone	   FGF19.	  Cancer	  Res.	  2014;74:3306-­‐16.	  8.	   Heinzle	   C,	   Erdem	   Z,	   Paur	   J,	   Grasl-­‐Kraupp	   B,	   Holzmann	   K,	   Grusch	   M,	   et	   al.	   Is	  fibroblast	  growth	  factor	  receptor	  4	  a	  suitable	  target	  of	  cancer	  therapy?	  Curr	  Pharm	  Des.	  2014;20:2881-­‐98.	  9.	   Herbert	   C,	   Lassalle	   G,	   Alcouffe	   C,	   Bono	   F.	   Approaches	   targeting	   the	   FGF-­‐FGFR	  system:	   a	   review	   of	   the	   recent	   patent	   literature	   and	   associated	   advanced	   therapeutic	  agents.	  Pharmaceutical	  patent	  analyst.	  2014;3:585-­‐612.	  10.	   Sawey	  ET,	  Chanrion	  M,	  Cai	  C,	  Wu	  G,	   Zhang	   J,	   Zender	  L,	   et	   al.	   Identification	  of	   a	  therapeutic	   strategy	   targeting	   amplified	   FGF19	   in	   liver	   cancer	   by	   Oncogenomic	  screening.	  Cancer	  Cell.	  2011;19:347-­‐58.	  	  
 
